A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.05.013 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Hannah Goulart und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Pyrazoles, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Institutes of Health, Incyte Corporation, National Cancer Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) represents a high-risk subtype of B-ALL. The disease is driven by a range of kinase-activating mutations, resulting in a similar gene expression profile to that of Ph-positive ALL, and one which may be targetable by JAK- or ABL-directed kinase inhibition. PATIENTS AND METHODS: We conducted a phase I/II trial to explore the safety and efficacy of ruxolitinib or dasatinib in combination with Hyper-CVAD chemotherapy for patients ≥ 10 years of age with relapsed and/or refractory Ph-like ALL (clinicaltrials.gov/NCT02115295). RESULTS: A total of 11 patients were enrolled (ruxolitinib cohort, n = 10; dasatinib cohort, n = 1) with a median age of 24 years. The median number of prior lines of treatment was 3. Genetic aberrations included CRLF2 overexpression (n = 8), HMBOX1-JAK2 fusion (n = 1), IGH-EPOR fusion (n = 1), and NUP214-ABL1 (n = 1). We observed no dose-limiting toxicities in the first 2 cohorts of patients receiving ruxolitinib (15 mg BID, n = 5 and 20 mg BID, n = 3), however enrollment of the third cohort (25 mg BID, n = 2) was terminated early due to slow accrual. The most common ≥ grade 3 adverse events were related to infectious complications. We observed overall low efficacy with 1/10 patients receiving ruxolitinib achieving complete remission with incomplete platelet count recovery. CONCLUSION: Continued efforts should focus on identifying optimal treatment strategies for this high-risk group of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Leukemia, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: njain@mdanderson.org.
Förderung
- National Institutes of Health
- Incyte Corporation
- National Cancer Institute
Zitieren
APA
Goulart, H., Jabbour, E., Short, N. J., Kadia, T. M., Pemmaraju, N., Takahashi, K., Ravandi, F., Konopleva, M., & Jain, N. (2025). A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.05.013
Vancouver
Goulart H, Jabbour E, Short NJ, Kadia TM, Pemmaraju N, Takahashi K, et al. A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.05.013
BibTeX
@article{Goulart2025,
author = {Goulart, Hannah and Jabbour, Elias and Short, Nicholas J and Kadia, Tapan M and Pemmaraju, Naveen and Takahashi, Koichi and Ravandi, Farhad and Konopleva, Marina and Jain, Nitin},
title = {A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.05.013}
}
EUVIMED